Novo touts SGLT2-topping data for blockbuster Victoza

SGLT2 drugs may be in the diabetes spotlight thanks to recent data showing that one of them--Eli Lilly ($LLY) and Boehringer Ingelheim's Jardiance--could cut cardiovascular risks. But Novo Nordisk ($NVO), maker of GLP-1 superstar Victoza, is striking back with some new data of its own. The company has rolled out a new meta-analysis showing that its therapy beat out SGLT2s at reducing the blood sugar metric HbA1c. More from FiercePharmaMarketing